A Multi-center, Randomized, Double-blind, Placebo Controlled Study to Investigate the Efficacy and Safety of Ligelizumab (QGE031) in the Treatment of Chronic Inducible Urticaria (CINDU) in Adolescents and Adults Inadequately Controlled With H1-antihistamines
Latest Information Update: 12 Mar 2024
At a glance
- Drugs Ligelizumab (Primary)
- Indications Chronic urticaria
- Focus Registrational; Therapeutic Use
- Acronyms PEARL-PROVOKE
- Sponsors Novartis Pharma A.G.; Novartis Pharmaceuticals
- 26 Jan 2023 Status changed from recruiting to discontinued.
- 18 Sep 2022 This trial has been discontinued in Netherlands (end date : 09-Aug-2022), according to European Clinical Trials Database record.
- 10 Sep 2022 This trial has been discontinued in Austria (Date of the global end of the trial : 09-Aug-2022), according to European Clinical Trials Database record.